Sutro initiated a collaboration with Merck in July, 2018, known as MSD outside the United States and Canada, to discover and develop novel immune-modulating therapies for cancer and autoimmune disorders.
The research and development activities will leverage Sutro’s proprietary cell-free protein synthesis and site-specific conjugation platforms, which facilitate precision design and rapid empirical optimization of protein conjugates, to discover and develop best-in-class immune-modulating cytokine derivatives for both oncology and autoimmune indications.
Under the agreement, Sutro will be primarily responsible for preclinical research and Merck will gain exclusive worldwide rights to therapeutic candidates derived from the collaboration.
Sutro will receive an upfront payment of $60 million and is eligible for milestone payments totaling up to $1.6 billion associated with the development and sale of all therapeutic candidates and all possible indications identified under the collaboration, as well as tiered royalties on the sale of products.

Learn More

Bristol-Myers Squibb

Sutro has collaborated with Bristol-Myers Squibb since 2012 on the discovery and development of Antibody Drug Conjugates (ADCs) and bispecific antibodies using Sutro’s Xpress CF™ technology. There are currently four programs in the collaboration, including a clinical stage ADC targeting B-Cell Maturation Antigen (BCMA-Targeting ADC), previously disclosed by Bristol-Myers Squibb. Bristol-Myers Squibb holds worldwide development and commercialization rights to the BCMA-targeting ADC program and Sutro manufactures cGMP clinical supply. Sutro has US development and commercialization rights to three preclinical stage immuno-oncology programs, BCMA-CD3, PD1-LAG3, and PD1-TIM3, with Bristol-Myers Squibb holding ex-US rights.

Learn More

EMD Serono

In September, 2014, Sutro announced a $300M+ collaboration with EMD Serono to discover and develop novel antibody drug conjugates for several targets in the field of oncology.  Sutro is responsible for identifying lead molecules and producing both preclinical and clinical material using its Xpress CF™ platform.

Learn More

If you are interested in exploring partnership opportunities with Sutro, contact us at